Observational studyBMC nephrology2026
Changes in uric acid levels and estimated glomerular filtration rate slope after treatment with dotinurad in patients with hyperuricemia.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia is a recognized risk factor for chronic kidney disease (CKD). Dotinurad, a novel selective urate reabsorption inhibitor, effectively lowers uric acid (UA) levels. However, longitudinal patterns of UA after treatment initiation and changes in estimated glomerular filtration rate (eGFR) slope across the pre-initiation and post-initiation periods remain insufficiently characterized.
methodsWe retrospectively identified patients with hyperuricemia who initiated dotinurad therapy. Eligible patients required a baseline eGFR and at least two eGFR measurements during both the pre-initiation period (3, 6, or 12 months before initiation) and the post-initiation period (3, 6, or 12 months after initiation). UA levels were assessed at baseline and at 3, 6, and 12 months. Longitudinal changes in UA and eGFR slopes were evaluated using linear mixed-effects models.
resultsAmong 135 screened patients, 68 met the inclusion criteria. The mean age was 59 years, and 73.5% were male. The median baseline eGFR was 50.4 mL/min/1.73 m². UA levels were lower at 3, 6, and 12 months compared with baseline (all P < 0.001). The annual eGFR slope was − 5.7 mL/min/1.73 m²/year (95% confidence interval [CI] − 8.3 to − 3.2) before initiation and 0.6 mL/min/1.73 m²/year (95% CI − 0.6 to 1.8) after initiation. The difference in slopes was statistically significant (P for interaction = 0.003). Similar patterns were observed in multivariable models adjusted for baseline eGFR, age, sex, and sodium–glucose cotransporter 2 inhibitor use.
conclusionIn this retrospective cohort, dotinurad use was associated with lower UA levels and a less negative eGFR slope over time. These findings describe real-world patterns of UA levels after treatment initiation and changes in eGFR slope before and after treatment initiation, and they support the need for prospective studies evaluating kidney outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.